glioblastoma (Cancer)
Information
- Disease name
- glioblastoma
- Disease ID
- DOID:3068
- Description
- "A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has_material_basis_in abnormally proliferating cells derives_from multiple cell types including astrocytes and oligondroctyes." [url:http\://cancergenome.nih.gov/cancersselected/glioblastomamultiforme, url:http\://en.wikipedia.org/wiki/Glioblastoma_multiforme, url:https\://www.ncbi.nlm.nih.gov/pubmed/20129251, url:https\://www.ncbi.nlm.nih.gov/pubmed/23029035]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| TP53 | 17 | 7,668,421 | 7,687,490 | 8 |
| BRAF | 7 | 140,719,337 | 140,924,929 | 6 |
| PTCH1 | 9 | 95,442,980 | 95,509,266 | 2 |
| H3-3A | 1 | 226,063,977 | 226,072,001 | 2 |
| CEBPA | 19 | 33,299,934 | 33,302,534 | 2 |
| CDKN2A | 9 | 21,968,056 | 21,974,866 | 2 |
| AR | X | 67,544,021 | 67,730,619 | 2 |
| CDKN2B-AS1 | 9 | 21,994,778 | 22,039,498 | 2 |
| NRAS | 1 | 114,704,469 | 114,716,771 | 2 |
| ERBB2 | 17 | 39,700,064 | 39,728,658 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03137888 | Active, not recruiting | Phase 2 | Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma | September 20, 2017 | January 4, 2025 |
| NCT04280848 | Active, not recruiting | Phase 2 | Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma | May 26, 2020 | December 2024 |
| NCT04225039 | Active, not recruiting | Phase 2 | Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | June 23, 2020 | June 2025 |
| NCT04221503 | Active, not recruiting | Phase 2 | Niraparib/TTFields in GBM | December 30, 2019 | December 2025 |
| NCT03535350 | Active, not recruiting | Phase 1 | Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma | August 24, 2018 | December 31, 2024 |
| NCT03532295 | Active, not recruiting | Phase 2 | Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas | April 20, 2020 | April 25, 2026 |
| NCT05538572 | Active, not recruiting | Phase 1 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | December 27, 2022 | December 2024 |
| NCT03514069 | Active, not recruiting | Phase 1 | Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma | June 5, 2018 | December 31, 2024 |
| NCT02617745 | Active, not recruiting | Phase 2 | Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid | November 30, 2015 | December 2024 |
| NCT03743662 | Active, not recruiting | Phase 2 | Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | November 12, 2018 | November 2024 |
| NCT03739372 | Active, not recruiting | N/A | Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma | November 28, 2018 | January 1, 2027 |
| NCT05187624 | Active, not recruiting | Phase 1 | A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma | April 5, 2022 | December 31, 2025 |
| NCT02152982 | Active, not recruiting | Phase 2/Phase 3 | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | December 15, 2014 | December 15, 2024 |
| NCT03491683 | Active, not recruiting | Phase 1/Phase 2 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | May 31, 2018 | December 31, 2024 |
| NCT02655601 | Active, not recruiting | Phase 2 | Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 | September 25, 2018 | December 2024 |
| NCT01752491 | Active, not recruiting | Phase 1 | A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme | April 1, 2013 | December 31, 2024 |
| NCT03732352 | Active, not recruiting | Phase 2 | 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma | November 28, 2018 | October 1, 2025 |
| NCT03481231 | Active, not recruiting | In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma | September 13, 2020 | September 14, 2024 | |
| NCT03477513 | Active, not recruiting | N/A | Personalized Radiation Therapy for GBM | March 1, 2018 | June 30, 2025 |
| NCT04216329 | Active, not recruiting | Phase 1 | Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | July 7, 2020 | July 30, 2026 |
| NCT02669173 | Active, not recruiting | Phase 1 | Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma | October 11, 2016 | November 1, 2024 |
| NCT05938387 | Active, not recruiting | Phase 1 | Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma | May 9, 2023 | March 30, 2026 |
| NCT04121455 | Active, not recruiting | Phase 1/Phase 2 | Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients | September 12, 2019 | December 2024 |
| NCT03212274 | Active, not recruiting | Phase 2 | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | January 30, 2019 | July 31, 2024 |
| NCT03174197 | Active, not recruiting | Phase 1/Phase 2 | Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | June 30, 2017 | June 30, 2025 |
| NCT02525692 | Active, not recruiting | Phase 2 | Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma | January 2016 | December 2023 |
| NCT03782415 | Active, not recruiting | Phase 1/Phase 2 | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma | December 29, 2018 | June 30, 2024 |
| NCT03688178 | Active, not recruiting | Phase 2 | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab | August 26, 2020 | March 2025 |
| NCT04606316 | Active, not recruiting | Phase 1 | Surgical Nivolumab And Ipilimumab For Recurrent GBM | February 1, 2021 | December 31, 2024 |
| NCT03475186 | Active, not recruiting | Phase 2 | Testing Ramipril to Prevent Memory Loss in People With Glioblastoma | March 25, 2019 | July 31, 2024 |
| NCT05698199 | Active, not recruiting | Phase 1 | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) | August 21, 2023 | March 2026 |
| NCT02717962 | Active, not recruiting | Phase 2 | Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting | January 20, 2017 | March 30, 2024 |
| NCT01817751 | Active, not recruiting | Phase 2 | Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma | April 11, 2013 | October 30, 2027 |
| NCT03661723 | Active, not recruiting | Phase 2 | Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma | September 28, 2018 | June 1, 2024 |
| NCT04826393 | Active, not recruiting | Phase 1 | ASP8374 + Cemiplimab in Recurrent Glioma | March 9, 2022 | December 30, 2024 |
| NCT04074785 | Active, not recruiting | Early Phase 1 | Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6 | December 13, 2019 | October 24, 2025 |
| NCT03452930 | Active, not recruiting | Phase 1 | Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma | August 13, 2018 | December 30, 2024 |
| NCT02761070 | Active, not recruiting | Phase 3 | Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III | July 11, 2016 | November 10, 2025 |
| NCT03452579 | Active, not recruiting | Phase 2 | Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM | May 21, 2018 | December 30, 2022 |
| NCT04485949 | Active, not recruiting | Phase 2 | A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma | March 20, 2023 | July 2027 |
| NCT03451799 | Active, not recruiting | Phase 1 | Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma | April 13, 2018 | May 2026 |
| NCT01849146 | Active, not recruiting | Phase 1 | Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma | August 19, 2013 | March 4, 2025 |
| NCT04047706 | Active, not recruiting | Phase 1 | Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | August 13, 2019 | June 1, 2025 |
| NCT01204684 | Active, not recruiting | Phase 2 | Dendritic Cell Vaccine for Patients With Brain Tumors | October 8, 2010 | January 31, 2026 |
| NCT04047303 | Active, not recruiting | Phase 1 | CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma | January 2, 2020 | May 30, 2024 |
| NCT04479241 | Active, not recruiting | Phase 2 | LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma | October 21, 2020 | March 2024 |
| NCT04019262 | Active, not recruiting | Phase 1/Phase 2 | Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma | December 14, 2021 | July 2029 |
| NCT03630289 | Active, not recruiting | N/A | Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM | July 27, 2018 | December 31, 2023 |
| NCT03405792 | Active, not recruiting | Phase 2 | Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) | February 23, 2018 | May 2024 |
| NCT06105619 | Active, not recruiting | Phase 2/Phase 3 | A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). | October 8, 2018 | December 31, 2024 |
| NCT05140902 | Active, not recruiting | N/A | Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom | March 28, 2022 | December 2025 |
| NCT04913337 | Active, not recruiting | Phase 1/Phase 2 | Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | June 9, 2021 | July 2025 |
| NCT04015700 | Active, not recruiting | Phase 1 | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | July 14, 2020 | December 31, 2024 |
| NCT03389230 | Active, not recruiting | Phase 1 | Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma | August 14, 2018 | June 14, 2024 |
| NCT02866747 | Active, not recruiting | Phase 1/Phase 2 | A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma | January 17, 2017 | April 2026 |
| NCT04900792 | Active, not recruiting | Phase 1 | A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma | February 28, 2023 | December 31, 2025 |
| NCT02375841 | Active, not recruiting | Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers | February 2015 | February 2025 | |
| NCT01535911 | Active, not recruiting | N/A | Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors | April 1, 2012 | June 1, 2026 |
| NCT03383978 | Active, not recruiting | Phase 1 | Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma | December 1, 2017 | June 30, 2026 |
| NCT05267106 | Active, not recruiting | Phase 2 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations | May 20, 2022 | November 29, 2024 |
| NCT01582269 | Active, not recruiting | Phase 2 | A Study in Recurrent Glioblastoma (GB) | April 26, 2012 | September 2024 |
| NCT03995706 | Active, not recruiting | Early Phase 1 | Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 | July 17, 2019 | July 2024 |
| NCT04868396 | Active, not recruiting | Patient-derived Glioma Stem Cell Organoids | April 10, 2021 | September 1, 2024 | |
| NCT03587038 | Active, not recruiting | Phase 1 | OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma | September 3, 2018 | November 2026 |
| NCT03347617 | Active, not recruiting | Phase 2 | Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma | December 20, 2017 | May 30, 2024 |
| NCT03344250 | Active, not recruiting | Phase 1 | Phase I EGFR BATs in Newly Diagnosed Glioblastoma | March 1, 2018 | December 8, 2024 |
| NCT02455557 | Active, not recruiting | Phase 2 | SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | May 4, 2015 | December 30, 2024 |
| NCT01430351 | Active, not recruiting | Phase 1 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | September 14, 2011 | September 30, 2025 |
| NCT02974738 | Active, not recruiting | Phase 1 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | December 7, 2016 | April 14, 2025 |
| NCT03244995 | Active, not recruiting | N/A | Mind-Body Intervention in Glioma Couples | August 6, 2017 | October 31, 2024 |
| NCT02981940 | Active, not recruiting | Phase 2 | A Study of Abemaciclib in Recurrent Glioblastoma | February 9, 2017 | June 2025 |
| NCT04545177 | Active, not recruiting | N/A | Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue | September 17, 2020 | December 2024 |
| NCT03581292 | Active, not recruiting | Phase 2 | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | November 6, 2018 | September 22, 2024 |
| NCT04406272 | Active, not recruiting | Phase 2 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | August 1, 2020 | August 1, 2024 |
| NCT04642937 | Active, not recruiting | Phase 1 | Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma | December 1, 2020 | November 2024 |
| NCT04397679 | Active, not recruiting | Phase 1 | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma | August 12, 2021 | April 27, 2026 |
| NCT06038604 | Active, not recruiting | N/A | Glioblastoma Psychosocial Support Program | November 3, 2023 | June 2024 |
| NCT04324840 | Active, not recruiting | Phase 1 | A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | July 10, 2020 | May 15, 2026 |
| NCT03050736 | Active, not recruiting | Phase 2 | Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression | December 17, 2017 | December 30, 2023 |
| NCT03223103 | Active, not recruiting | Phase 1 | Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma | March 1, 2018 | May 2025 |
| NCT03797326 | Active, not recruiting | Phase 2 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | February 12, 2019 | December 20, 2024 |
| NCT06404034 | Available | Expanded Access to Gallium Maltolate (GaM) | |||
| NCT05551013 | Available | Treatment of Recurrent GBM With APG-157 Via Expanded Access | |||
| NCT04566393 | Available | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | |||
| NCT05974410 | Available | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | |||
| NCT00960492 | Completed | Phase 1 | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma | September 2009 | October 2013 |
| NCT00961090 | Completed | Phase 2 | Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery | September 2009 | April 23, 2015 |
| NCT00973557 | Completed | The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function | September 2009 | January 2012 | |
| NCT00977431 | Completed | Phase 1 | Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform | September 17, 2009 | September 12, 2017 |
| NCT01004874 | Completed | Phase 2 | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma | December 30, 2009 | November 2, 2021 |
| NCT05131815 | Completed | N/A | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors | January 10, 2022 | August 21, 2023 |
| NCT01043536 | Completed | Phase 1 | Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults | September 2009 | |
| NCT05039346 | Completed | Quality of Life and Patient Needs in Advanced High Grade Gliomas | February 11, 2012 | January 30, 2023 | |
| NCT01067469 | Completed | Phase 2 | Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | January 2010 | October 2016 |
| NCT01082926 | Completed | Phase 1 | Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | May 2010 | September 2013 |
| NCT04974983 | Completed | Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma | September 1, 2017 | August 30, 2020 | |
| NCT01100177 | Completed | Phase 2 | Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients | June 2009 | January 2012 |
| NCT01111097 | Completed | Phase 1 | Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors | April 2010 | March 2014 |
| NCT01112527 | Completed | Phase 2 | PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma | April 2010 | September 2015 |
| NCT01120639 | Completed | Phase 1/Phase 2 | Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform | April 2010 | November 15, 2020 |
| NCT01149109 | Completed | Phase 3 | Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients | October 2010 | April 6, 2017 |
| NCT01149850 | Completed | Phase 2 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | April 28, 2010 | December 8, 2023 |
| NCT01156584 | Completed | Phase 1 | A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma | July 2010 | August 18, 2016 |
| NCT01171469 | Completed | Phase 1 | Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | September 2010 | June 2012 |
| NCT04846257 | Completed | Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict Recurrence | January 1, 2018 | February 1, 2021 | |
| NCT04814329 | Completed | Glioblastoma Response Prediction to Apatinib | April 22, 2021 | June 30, 2023 | |
| NCT04716699 | Completed | Phase 1 | Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma | January 20, 2021 | January 24, 2022 |
| NCT04657315 | Completed | Phase 1/Phase 2 | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients | June 24, 2020 | December 22, 2022 |
| NCT01240460 | Completed | Phase 1 | Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection | January 2011 | June 2012 |
| NCT01242566 | Completed | Phase 2 | Temozolomide in Elderly Patients With KPS < 70 | July 2007 | September 2010 |
| NCT01250470 | Completed | Phase 1 | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma | September 5, 2012 | May 29, 2014 |
| NCT01259869 | Completed | Phase 2 | A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression | April 1, 2011 | February 13, 2015 |
| NCT01291420 | Completed | Phase 1/Phase 2 | Dendritic Cell Vaccination for Patients With Solid Tumors | May 3, 2010 | May 5, 2018 |
| NCT04630379 | Completed | N/A | Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers | June 13, 2018 | August 31, 2020 |
| NCT04610229 | Completed | N/A | Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. | February 1, 2016 | August 26, 2019 |
| NCT01310868 | Completed | Phase 2 | Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma | May 2011 | March 2015 |
| NCT01331291 | Completed | Phase 2 | Bosutinib in Adult Patients With Recurrent Glioblastoma | April 2011 | December 2014 |
| NCT01339052 | Completed | Phase 2 | Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma | September 2011 | February 2019 |
| NCT01345370 | Completed | Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients | March 2009 | June 2015 | |
| NCT04604158 | Completed | N/A | Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients | December 2, 2020 | May 17, 2024 |
| NCT01364064 | Completed | Phase 3 | Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma | January 2007 | June 2008 |
| NCT01380782 | Completed | Phase 2 | BIBF 1120 for Recurrent High-Grade Gliomas | May 2012 | July 2014 |
| NCT01383135 | Completed | Early Phase 1 | Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 | October 2010 | December 2013 |
| NCT01392209 | Completed | Phase 1 | Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma | July 8, 2011 | November 15, 2019 |
| NCT04596930 | Completed | N/A | MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma | January 22, 2021 | May 31, 2022 |
| NCT04552886 | Completed | Phase 1 | Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma | October 11, 2021 | December 1, 2023 |
| NCT01421524 | Completed | Phase 1 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | September 12, 2011 | November 21, 2023 |
| NCT01434602 | Completed | Phase 1/Phase 2 | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | October 2, 2012 | July 13, 2021 |
| NCT01443676 | Completed | Phase 2 | Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma | October 2011 | August 2016 |
| NCT04516733 | Completed | N/A | Precoce Medical Care by the Mobil Support for Patients With Glioblastoma | May 10, 2019 | February 15, 2022 |
| NCT01454596 | Completed | Phase 1/Phase 2 | CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII | May 16, 2012 | January 17, 2019 |
| NCT01465347 | Completed | Phase 1/Phase 2 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma | February 2012 | February 2016 |
| NCT01473901 | Completed | Phase 1 | A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | December 30, 2011 | May 17, 2017 |
| NCT01478178 | Completed | Phase 1/Phase 2 | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma | October 2011 | October 2016 |
| NCT01480479 | Completed | Phase 3 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | November 2011 | November 2016 |
| NCT01491893 | Completed | Phase 1 | PVSRIPO for Recurrent Glioblastoma (GBM) | April 25, 2012 | October 1, 2021 |
| NCT01493219 | Completed | Biomarkers for Prognosis of Glioblastoma (GBM) | September 20, 2011 | September 1, 2017 | |
| NCT01498328 | Completed | Phase 2 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma | December 2011 | May 17, 2016 |
| NCT01502241 | Completed | Phase 3 | Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly | January 2005 | November 2011 |
| NCT01514201 | Completed | Phase 1/Phase 2 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | February 1, 2012 | March 28, 2018 |
| NCT01516905 | Completed | PET/CT Imaging of Malignant Brain Tumors With 124I-NM404 | December 2011 | May 17, 2016 | |
| NCT01520870 | Completed | Phase 2 | Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. | February 2012 | March 9, 2017 |
| NCT01522820 | Completed | Phase 1 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | March 2012 | July 2016 |
| NCT01564914 | Completed | Phase 2 | A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma | May 2012 | June 2015 |
| NCT04446416 | Completed | N/A | Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients | July 21, 2020 | August 4, 2023 |
| NCT01598597 | Completed | An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite) | March 2012 | November 2014 | |
| NCT01602588 | Completed | Phase 2 | A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG) | May 2013 | November 2017 |
| NCT01604590 | Completed | Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme | July 2012 | September 2014 | |
| NCT01609790 | Completed | Phase 2 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | June 4, 2012 | May 20, 2022 |
| NCT01632228 | Completed | Phase 2 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | June 29, 2012 | January 21, 2016 |
| NCT01653834 | Completed | N/A | Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas | July 2012 | March 2014 |
| NCT01723020 | Completed | Phase 1 | A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | December 27, 2012 | September 25, 2017 |
| NCT01740258 | Completed | Phase 2 | Bevacizumab Beyond Progression (BBP) | January 2013 | November 14, 2019 |
| NCT04205357 | Completed | Phase 1 | Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma | March 1, 2020 | October 14, 2022 |
| NCT04119674 | Completed | Phase 1/Phase 2 | Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma | March 19, 2019 | August 23, 2022 |
| NCT01810744 | Completed | N/A | Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma | May 2013 | May 2015 |
| NCT04116138 | Completed | Phase 1/Phase 2 | Antisecretory Factor in Primary Glioblastoma 1 | September 1, 2019 | March 31, 2021 |
| NCT01813877 | Completed | N/A | Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma | August 22, 2012 | January 14, 2020 |
| NCT01836536 | Completed | N/A | Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients | September 2012 | August 2015 |
| NCT01846871 | Completed | Phase 2 | Tivozanib for Recurrent Glioblastoma | June 2013 | May 2016 |
| NCT01851733 | Completed | Phase 1 | MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme | August 13, 2013 | May 30, 2018 |
| NCT01860638 | Completed | Phase 2 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | August 19, 2013 | May 5, 2017 |
| NCT01867593 | Completed | Early Phase 1 | MET-PET for Newly Diagnosed Glioblastoma | January 2014 | September 2016 |
| NCT01872221 | Completed | N/A | Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study | May 2013 | April 2018 |
| NCT01880008 | Completed | Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma | April 2008 | August 2012 | |
| NCT04006119 | Completed | Phase 2 | Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma | August 1, 2019 | August 5, 2021 |
| NCT01905228 | Completed | Phase 1 | A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm | July 2013 | June 2019 |
| NCT01907165 | Completed | Early Phase 1 | Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide | October 10, 2013 | February 9, 2018 |
| NCT01922076 | Completed | Phase 1 | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | September 3, 2013 | September 30, 2022 |
| NCT01931098 | Completed | Phase 2 | Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab | December 10, 2015 | September 12, 2019 |
| NCT00001148 | Completed | Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor | October 1999 | January 2005 | |
| NCT01957956 | Completed | Early Phase 1 | Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | November 11, 2013 | November 16, 2016 |
| NCT01967810 | Completed | Phase 2 | ANG1005 in Patients With Recurrent High-Grade Glioma | October 2013 | September 2017 |
| NCT01975116 | Completed | Phase 1 | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors | August 2013 | April 2015 |
| NCT03926507 | Completed | N/A | F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery | April 30, 2019 | September 18, 2023 |
| NCT03877861 | Completed | Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms | March 15, 2018 | May 1, 2021 | |
| NCT01989884 | Completed | Phase 2 | An Efficacy Study Of Ortataxel In Recurrent Glioblastoma | November 2013 | December 2016 |
| NCT02010606 | Completed | Phase 1 | Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma | January 8, 2014 | July 10, 2021 |
| NCT02014844 | Completed | Phase 2 | Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma | March 2014 | December 2016 |
| NCT03778294 | Completed | Phase 2 | 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy | March 28, 2019 | November 26, 2023 |
| NCT03776071 | Completed | Phase 3 | A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 | December 16, 2020 | February 29, 2024 |
| NCT03770468 | Completed | Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma | July 5, 2015 | August 18, 2023 | |
| NCT02092038 | Completed | Phase 1 | Preoperative Chemoradiation for Glioblastoma | November 2014 | July 2015 |
| NCT02149225 | Completed | Phase 1 | GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients | October 2014 | June 2018 |
| NCT02157103 | Completed | Phase 2 | A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma | January 2014 | January 2018 |
| NCT03726515 | Completed | Phase 1 | CART-EGFRvIII + Pembrolizumab in GBM | March 11, 2019 | February 27, 2021 |
| NCT02206230 | Completed | Phase 2 | Trial of Hypofractionated Radiation Therapy for Glioblastoma | September 25, 2014 | February 14, 2023 |
| NCT02207010 | Completed | Early Phase 1 | A Phase 0 Study of AZD1775 in Recurrent GBM Patients | July 2014 | March 25, 2019 |
| NCT02209948 | Completed | Phase 2 | Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma. | August 22, 2014 | June 14, 2019 |
| NCT02238496 | Completed | Phase 1 | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | December 8, 2014 | February 14, 2021 |
| NCT02253212 | Completed | Phase 1/Phase 2 | Safety of BBB Opening With the SonoCloud | July 2014 | July 2018 |
| NCT03687099 | Completed | Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma | April 30, 2018 | November 8, 2019 | |
| NCT03679754 | Completed | Phase 1 | Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 | September 5, 2018 | January 19, 2021 |
| NCT02315534 | Completed | Phase 1/Phase 2 | A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma | March 2015 | June 24, 2019 |
| NCT02327078 | Completed | Phase 1/Phase 2 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | November 26, 2014 | June 16, 2020 |
| NCT03636477 | Completed | Phase 1 | A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 | June 18, 2018 | June 30, 2021 |
| NCT02330562 | Completed | Phase 1/Phase 2 | Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab | April 15, 2015 | June 2, 2021 |
| NCT02330991 | Completed | Phase 2 | A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse | January 2015 | September 2020 |
| NCT02336165 | Completed | Phase 2 | Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma | February 26, 2015 | July 6, 2021 |
| NCT02337491 | Completed | Phase 2 | Pembrolizumab +/- Bevacizumab for Recurrent GBM | February 9, 2015 | September 14, 2020 |
| NCT02342379 | Completed | Phase 2 | TH-302 in Combination With Bevacizumab for Glioblastoma | May 2015 | December 4, 2019 |
| NCT02343406 | Completed | Phase 2 | Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas | February 17, 2015 | June 24, 2019 |
| NCT02359097 | Completed | N/A | Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma | January 6, 2015 | March 12, 2021 |
| NCT02366728 | Completed | Phase 2 | DC Migration Study for Newly-Diagnosed GBM | October 12, 2015 | October 31, 2020 |
| NCT02367482 | Completed | Tryptophan Metabolism in Human Brain Tumors | July 2014 | December 31, 2023 | |
| NCT03626896 | Completed | N/A | Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients | August 17, 2018 | June 19, 2019 |
| NCT02374255 | Completed | N/A | Improving Goals of Care Discussion in Advanced Cancer Patients | March 15, 2016 | May 16, 2018 |
| NCT02379572 | Completed | N/A | Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas | June 2015 | July 1, 2021 |
| NCT03616860 | Completed | N/A | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma | October 16, 2018 | December 31, 2023 |
| NCT03615404 | Completed | Phase 1 | Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma | October 5, 2018 | July 2, 2020 |
| NCT02410577 | Completed | N/A | 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme | April 2015 | August 2018 |
| NCT03603379 | Completed | Phase 1 | Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas | November 16, 2018 | November 1, 2020 |
| NCT02431572 | Completed | N/A | A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy | May 2015 | February 2019 |
| NCT02457845 | Completed | Phase 1 | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | May 2016 | January 2024 |
| NCT02458508 | Completed | Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy | March 2015 | March 2017 | |
| NCT02465268 | Completed | Phase 2 | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme | August 9, 2016 | November 30, 2023 |
| NCT02466828 | Completed | Early Phase 1 | qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia. | March 2015 | April 2018 |
| NCT02473484 | Completed | Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas | June 24, 2014 | October 2017 | |
| NCT02478164 | Completed | Phase 2 | Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma | July 13, 2015 | May 9, 2018 |
| NCT02490930 | Completed | Early Phase 1 | A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma | July 2015 | September 2017 |
| NCT02511405 | Completed | Phase 3 | A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) | August 2015 | September 30, 2018 |
| NCT03551249 | Completed | N/A | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption | March 26, 2019 | December 31, 2023 |
| NCT02529072 | Completed | Phase 1 | Nivolumab With DC Vaccines for Recurrent Brain Tumors | January 2016 | December 30, 2019 |
| NCT02573324 | Completed | Phase 3 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification | January 4, 2015 | April 4, 2022 |
| NCT02575027 | Completed | N/A | Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme | November 12, 2014 | June 20, 2018 |
| NCT03539731 | Completed | Phase 1 | [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers | April 23, 2018 | December 31, 2022 |
| NCT02605746 | Completed | Early Phase 1 | Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis | February 17, 2016 | July 12, 2019 |
| NCT03493932 | Completed | Phase 1 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | September 24, 2018 | June 27, 2023 |
| NCT02630030 | Completed | Early Phase 1 | Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma | March 24, 2016 | September 3, 2020 |
| NCT02631655 | Completed | N/A | POSitron Emission Imaging Using 18F-FDOPA in Neurooncology | December 2015 | June 2020 |
| NCT02644291 | Completed | Phase 1 | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | May 2016 | June 9, 2022 |
| NCT02658981 | Completed | Phase 1 | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | August 24, 2016 | October 3, 2023 |
| NCT02661282 | Completed | Phase 1/Phase 2 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | June 1, 2016 | February 23, 2022 |
| NCT02666066 | Completed | Radiomics for Prediction of Survival in GBM | January 2016 | July 2018 | |
| NCT02678975 | Completed | Phase 2/Phase 3 | Disulfiram in Recurrent Glioblastoma | January 2017 | January 15, 2021 |
| NCT02684058 | Completed | Phase 2 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | December 28, 2017 | April 28, 2023 |
| NCT03477110 | Completed | Early Phase 1 | Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma | May 4, 2018 | January 26, 2024 |
| NCT02698280 | Completed | Phase 2 | Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma | July 2015 | May 2018 |
| NCT02709616 | Completed | Phase 1 | Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC) | March 1, 2016 | June 30, 2019 |
| NCT03466450 | Completed | Phase 1/Phase 2 | Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma | March 15, 2018 | November 29, 2023 |
| NCT02718443 | Completed | Phase 1 | VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma | May 2016 | July 2018 |
| NCT02725684 | Completed | Using Genomic Analysis to Guide Individual Treatment in Glioblastoma | March 12, 2015 | July 7, 2017 | |
| NCT02728349 | Completed | Phase 1 | Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma | April 12, 2016 | September 13, 2017 |
| NCT03454295 | Completed | Early Phase 1 | Easing Psychosocial Burden for Informal Caregivers | February 12, 2018 | March 26, 2024 |
| NCT02750891 | Completed | Phase 1/Phase 2 | A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas | April 2016 | January 2020 |
| NCT02768389 | Completed | Early Phase 1 | Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma | September 6, 2016 | November 2018 |
| NCT03139916 | Completed | Phase 2 | Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma | September 13, 2017 | August 31, 2022 |
| NCT03439332 | Completed | Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma | February 7, 2018 | March 1, 2019 | |
| NCT02798406 | Completed | Phase 2 | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | October 6, 2016 | June 30, 2021 |
| NCT02799238 | Completed | Phase 2 | Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma | March 2016 | February 24, 2020 |
| NCT03434262 | Completed | Phase 1 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | March 5, 2018 | May 24, 2024 |
| NCT02808364 | Completed | Phase 1 | Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2) | March 1, 2016 | June 30, 2019 |
| NCT03426891 | Completed | Phase 1 | Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | March 16, 2018 | June 28, 2023 |
| NCT02843230 | Completed | Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI | August 1, 2016 | January 31, 2022 | |
| NCT02844439 | Completed | Phase 2 | Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma | June 2016 | April 30, 2020 |
| NCT02858895 | Completed | Phase 2 | Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | April 11, 2017 | October 31, 2019 |
| NCT03390569 | Completed | N/A | Exercise in Patients With Glioblastoma | August 29, 2017 | December 23, 2021 |
| NCT02869243 | Completed | Phase 1 | A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients | July 18, 2017 | June 30, 2021 |
| NCT02871843 | Completed | Phase 1 | RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas | February 14, 2017 | September 19, 2021 |
| NCT03388372 | Completed | Phase 2 | Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma | August 18, 2010 | March 23, 2017 |
| NCT02887417 | Completed | Glioblastoma Platelet Activation Study | January 2016 | December 2016 | |
| NCT02893137 | Completed | Phase 1 | Enhancing Optune Therapy With Targeted Craniectomy | October 1, 2016 | May 31, 2019 |
| NCT02899663 | Completed | MRI Detection of Microbleeds in Glioma Patients | January 2015 | ||
| NCT03374943 | Completed | Phase 1 | A Trial of KB004 in Patients With Glioblastoma | December 5, 2017 | September 22, 2021 |
| NCT02903069 | Completed | Phase 1 | Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer | August 17, 2016 | January 25, 2021 |
| NCT03355794 | Completed | Phase 1 | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | November 14, 2017 | July 31, 2022 |
| NCT03341806 | Completed | Phase 1 | Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma | June 13, 2018 | October 13, 2021 |
| NCT02942264 | Completed | Phase 1/Phase 2 | Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | December 14, 2016 | August 26, 2020 |
| NCT02968940 | Completed | Phase 2 | Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | March 17, 2017 | August 29, 2019 |
| NCT02997423 | Completed | Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM) | November 30, 2016 | November 30, 2022 | |
| NCT03243851 | Completed | Phase 2 | Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma | November 21, 2016 | December 31, 2020 |
| NCT03018288 | Completed | Phase 2 | Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) | September 21, 2017 | December 20, 2022 |
| NCT03020602 | Completed | Phase 1 | BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab | January 4, 2017 | June 26, 2021 |
| NCT03224104 | Completed | Phase 1 | Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma | June 12, 2018 | May 5, 2022 |
| NCT03043391 | Completed | Phase 1 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | November 7, 2017 | March 23, 2022 |
| NCT03048240 | Completed | N/A | INtraoperative photoDYnamic Therapy of GliOblastoma | May 5, 2017 | April 28, 2021 |
| NCT03075514 | Completed | N/A | Ketogenic Diets as an Adjuvant Therapy in Glioblastoma | April 1, 2017 | March 5, 2019 |
| NCT03149003 | Completed | Phase 3 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | December 8, 2017 | August 30, 2021 |
| NCT02770378 | Completed | Phase 1/Phase 2 | A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma | November 2016 | December 2020 |
| NCT00001171 | Completed | Evaluation of Factors in Human Brain Tumors | July 1979 | September 2005 | |
| NCT00009035 | Completed | Natural History of Patients With Brain and Spinal Cord Tumors | January 22, 2001 | September 11, 2018 | |
| NCT00028158 | Completed | Phase 1/Phase 2 | Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer | December 2001 | October 2003 |
| NCT00029783 | Completed | Phase 2 | Efficacy of Distant Healing in Glioblastoma Treatment | September 2000 | June 2005 |
| NCT00068952 | Completed | Phase 3 | Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme | August 2003 | March 2006 |
| NCT00074646 | Completed | Phase 1 | Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas | December 2003 | June 2005 |
| NCT00080054 | Completed | Phase 1 | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | ||
| NCT00087451 | Completed | Phase 1 | Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) | July 2004 | November 2005 |
| NCT00088400 | Completed | Phase 3 | Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors | July 2004 | November 2005 |
| NCT00100802 | Completed | Phase 2 | Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas | March 21, 2005 | June 30, 2017 |
| NCT00115440 | Completed | Phase 1/Phase 2 | BNCT to Treat Glioma That Has Progressed Following Radiotherapy | March 2001 | January 2009 |
| NCT00132158 | Completed | Phase 1 | ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors | September 2005 | October 2011 |
| NCT00165477 | Completed | Phase 2 | Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme | September 2005 | July 2009 |
| NCT00179803 | Completed | Phase 2 | Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors | March 1998 | September 2009 |
| NCT00190424 | Completed | Phase 2 | Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma | September 2005 | October 2010 |
| NCT00200161 | Completed | Phase 2 | Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma | August 9, 2005 | May 4, 2017 |
| NCT00238797 | Completed | Phase 2 | A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme | February 2003 | March 2006 |
| NCT00250211 | Completed | Phase 1/Phase 2 | Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide | March 2005 | April 2011 |
| NCT00295815 | Completed | Phase 3 | Enzastaurin Versus Lomustine in Glioblastoma | January 2006 | May 2014 |
| NCT00335075 | Completed | Phase 3 | Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) | March 2, 2005 | February 23, 2006 |
| NCT00337883 | Completed | Phase 2 | A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) | July 2003 | October 2005 |
| NCT00345163 | Completed | Phase 2 | A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN) | July 2006 | September 2007 |
| NCT00354913 | Completed | Phase 2 | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | May 2005 | October 2010 |
| NCT00385853 | Completed | Phase 1 | PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs | September 2006 | September 2011 |
| NCT00392171 | Completed | Phase 2 | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | June 9, 2006 | September 15, 2009 |
| NCT00397072 | Completed | Phase 2 | Epothilone in Recurrent Glioblastoma Patients | June 2006 | December 2008 |
| NCT00402116 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | September 2006 | December 2009 |
| NCT00431561 | Completed | Phase 2 | Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma | April 2003 | March 2009 |
| NCT05873946 | Completed | Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery | June 1, 2018 | July 30, 2023 | |
| NCT00525525 | Completed | Phase 2 | Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma | September 2007 | May 2013 |
| NCT00575887 | Completed | Phase 2 | Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma | August 2006 | March 2009 |
| NCT00576537 | Completed | Phase 2 | Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors | March 2001 | October 2011 |
| NCT00576641 | Completed | Phase 1 | Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma | May 2007 | April 2012 |
| NCT00597402 | Completed | Phase 2 | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | July 2007 | May 2013 |
| NCT00606008 | Completed | Phase 2 | A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma | March 2007 | August 2012 |
| NCT00609999 | Completed | Phase 1 | Ph I Dasatinib + Erlotinib in Recurrent MG | January 2008 | July 2010 |
| NCT00610571 | Completed | Phase 1 | Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | April 2004 | April 2012 |
| NCT00611325 | Completed | Phase 2 | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | May 2008 | October 2013 |
| NCT00611728 | Completed | Phase 1 | Ph I SU011248 + Irinotecan in Treatment of Pts w MG | March 2008 | September 2010 |
| NCT00612339 | Completed | Phase 2 | Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | August 2007 | May 2012 |
| NCT00612430 | Completed | Phase 2 | Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | March 2007 | September 2011 |
| NCT00612638 | Completed | Phase 1 | Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas | January 2005 | July 2008 |
| NCT00612651 | Completed | Phase 1 | PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas | October 2005 | June 2011 |
| NCT00612989 | Completed | Phase 1 | Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | February 2005 | July 2008 |
| NCT00613028 | Completed | Phase 2 | Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | April 2008 | January 2011 |
| NCT00613054 | Completed | Phase 1 | Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | November 2007 | April 2009 |
| NCT00613132 | Completed | Phase 1 | Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG | May 2005 | January 2013 |
| NCT00613223 | Completed | Phase 1 | Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | February 2008 | May 2011 |
| NCT00615927 | Completed | Phase 2 | Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | February 2006 | June 2012 |
| NCT00616005 | Completed | Phase 2 | Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide | November 2005 | June 2009 |
| NCT00624728 | Completed | Phase 1/Phase 2 | Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP) | February 2008 | November 2011 |
| NCT00657267 | Completed | Phase 2 | Dose-Intense Temozolomide in Recurrent Glioblastoma | May 2008 | October 2013 |
| NCT00667394 | Completed | Phase 2 | Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | April 2008 | July 2011 |
| NCT00671970 | Completed | Phase 2 | Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | February 2007 | April 2010 |
| NCT00672243 | Completed | Phase 2 | Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | April 2007 | December 2009 |
| NCT00684567 | Completed | Phase 2 | Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED) | September 27, 2005 | October 31, 2007 |
| NCT00686725 | Completed | Phase 4 | Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) | June 24, 2008 | September 28, 2011 |
| NCT00687765 | Completed | Phase 1/Phase 2 | Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma | July 2008 | June 2015 |
| NCT00689221 | Completed | Phase 3 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status | September 2008 | August 2013 |
| NCT00693095 | Completed | Phase 1 | Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer | September 2008 | April 2015 |
| NCT00694837 | Completed | Phase 1 | Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma | March 2009 | January 2013 |
| NCT00704808 | Completed | Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739) | May 2006 | December 2008 | |
| NCT00723827 | Completed | Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2) | March 2008 | September 2011 | |
| NCT00725010 | Completed | Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816) | April 2007 | April 2009 | |
| NCT05476341 | Completed | Phase 1 | A Phase I Clinical Trial of Bevacizumab Injection | April 6, 2017 | August 18, 2017 |
| NCT00734682 | Completed | Phase 1 | A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas | August 2008 | December 2014 |
| NCT00762255 | Completed | Phase 1 | A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma | September 2008 | July 2013 |
| NCT00777686 | Completed | Measuring Non-Enhancing Glioblastoma Progression | August 2008 | March 2011 | |
| NCT00780819 | Completed | N/A | Borderzone Sampling | October 2008 | December 2012 |
| NCT00807027 | Completed | Phase 3 | Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea | December 2008 | October 2012 |
| NCT00813943 | Completed | Phase 2 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status | March 2009 | August 2013 |
| NCT00821080 | Completed | Phase 1 | Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma | October 2008 | February 2015 |
| NCT00846456 | Completed | Phase 1/Phase 2 | Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma | January 2009 | February 2013 |
| NCT00864864 | Completed | Early Phase 1 | Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma | May 2007 | May 2013 |
| NCT00870181 | Completed | Phase 2 | ADV-TK Improves Outcome of Recurrent High-Grade Glioma | January 2008 | December 2012 |
| NCT00884416 | Completed | Phase 1 | Sorafenib in Newly Diagnosed High Grade Glioma | March 2009 | March 2012 |
| NCT00884741 | Completed | Phase 3 | Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma | April 15, 2009 | March 17, 2013 |
| NCT05171127 | Completed | Differentiation Between Healthy Cerebral Tissue and Tumor Tissue Using a Tissue Sensing Instrument | April 30, 2019 | December 31, 2022 | |
| NCT00906893 | Completed | Phase 2 | Evaluation of [18F]-FMISO for Non Operated Glioblastoma | June 2009 | January 2013 |
| NCT00921167 | Completed | Phase 2 | A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas | June 2009 | December 2013 |
| NCT00939991 | Completed | Phase 1/Phase 2 | Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas | October 2009 | April 2013 |
| NCT00941460 | Completed | Phase 2 | Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma | September 2009 | June 2013 |
| NCT00943826 | Completed | Phase 3 | A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma | June 29, 2009 | September 9, 2015 |
| NCT00944801 | Completed | Phase 1/Phase 2 | Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma | July 2002 | May 2009 |
| NCT03951142 | Enrolling by invitation | Phase 2 | Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study | October 1, 2019 | December 31, 2024 |
| NCT04599647 | No longer available | EAP for the Treatment of Glioblastoma With PVSRIPO | |||
| NCT04802447 | No longer available | SurVaxM Expanded Access Protocol | |||
| NCT04289155 | No longer available | Individual Patient Compassionate Use of GX-I7 | |||
| NCT03460782 | No longer available | An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas | |||
| NCT06439420 | Not yet recruiting | Phase 2 | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial | July 1, 2024 | November 30, 2026 |
| NCT04157478 | Not yet recruiting | Phase 2 | Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma | January 2020 | December 2024 |
| NCT06368934 | Not yet recruiting | N/A | Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma | April 8, 2024 | June 2027 |
| NCT05641220 | Not yet recruiting | Biopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study. | January 1, 2023 | January 1, 2027 | |
| NCT06102525 | Not yet recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma | October 2023 | May 2029 |
| NCT06132438 | Not yet recruiting | Phase 1 | Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma | November 2023 | September 2026 |
| NCT05095441 | Not yet recruiting | Phase 1 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | March 15, 2023 | April 30, 2026 |
| NCT05843253 | Not yet recruiting | Phase 2 | Study of Ribociclib and Everolimus in HGG and DIPG | May 30, 2024 | May 30, 2034 |
| NCT06385132 | Not yet recruiting | Psychological and Psychiatric prOfile in Glioblastoma and Head and Neck Cancer | April 15, 2024 | October 31, 2025 | |
| NCT06455189 | Not yet recruiting | Phase 1 | Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas | December 2024 | December 31, 2029 |
| NCT04536649 | Not yet recruiting | Phase 3 | Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma. | October 1, 2020 | September 30, 2025 |
| NCT05656300 | Not yet recruiting | Glioblastoma Imaging Using a Strong Iron-like Bloodpool Contrast Medium? | April 1, 2023 | April 1, 2025 | |
| NCT06061809 | Not yet recruiting | Phase 2 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | July 17, 2024 | December 31, 2030 |
| NCT06388733 | Not yet recruiting | Phase 3 | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma | June 2024 | March 2028 |
| NCT05839379 | Not yet recruiting | Targeted Pediatric High-Grade Glioma Therapy | May 30, 2024 | May 30, 2034 | |
| NCT06336291 | Not yet recruiting | Phase 2 | A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence | June 2024 | June 2026 |
| NCT06333899 | Not yet recruiting | Early Phase 1 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | September 1, 2024 | September 1, 2034 |
| NCT06017063 | Not yet recruiting | N/A | Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields | October 2023 | September 2026 |
| NCT04903795 | Not yet recruiting | Phase 1 | Bispecific T Cell Engager BRiTE for Patients With Grade IV Malignant Glioma | December 2026 | December 2026 |
| NCT06329570 | Not yet recruiting | Phase 1/Phase 2 | Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) | July 1, 2024 | March 31, 2027 |
| NCT05820191 | Not yet recruiting | Phase 2 | B-amyloid as a Marker for GBM Bioimaging | July 2024 | July 2026 |
| NCT05811793 | Not yet recruiting | N/A | Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma. | April 15, 2023 | December 30, 2025 |
| NCT06176066 | Not yet recruiting | N/A | PH Sensitive MRI Based Resections of Glioblastoma | January 1, 2024 | January 1, 2029 |
| NCT05541042 | Not yet recruiting | Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers | December 1, 2022 | November 1, 2027 | |
| NCT05990556 | Not yet recruiting | N/A | Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients | September 1, 2023 | September 1, 2028 |
| NCT05728125 | Not yet recruiting | Pinpointing the Factors Affecting Clinical Trial Experiences of Glioblastoma Patients | March 2024 | March 2026 | |
| NCT05539339 | Not yet recruiting | N/A | Personalized Trial in ctDNA-level-relapse Glioblastoma | December 1, 2022 | June 1, 2025 |
| NCT05683808 | Not yet recruiting | Phase 2 | Venous Thromboembolism Prevention in Outpatients With Glioma | January 16, 2023 | December 31, 2024 |
| NCT05773664 | Not yet recruiting | Phase 1 | Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma | August 15, 2024 | November 29, 2024 |
| NCT05439278 | Not yet recruiting | Phase 3 | Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma | August 1, 2022 | July 31, 2027 |
| NCT04933422 | Not yet recruiting | Phase 1 | CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) | January 2025 | July 2028 |
| NCT06136611 | Not yet recruiting | N/A | Preoperative Preradiotherapy TTFields | February 1, 2024 | December 1, 2025 |
| NCT06113705 | Not yet recruiting | N/A | Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study. | November 1, 2023 | December 31, 2026 |
| NCT05502991 | Not yet recruiting | Phase 2 | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma | December 11, 2022 | December 2027 |
| NCT05512195 | Not yet recruiting | N/A | Safety and Efficacy of a New Approach to Delineating Clinical Target Volume of Glioblastoma | September 1, 2022 | August 31, 2025 |
| NCT05513859 | Not yet recruiting | N/A | Investigational Imaging Technique During Brain Surgery | June 30, 2024 | June 23, 2025 |
| NCT06222138 | Not yet recruiting | N/A | Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma | June 2024 | October 2027 |
| NCT05515133 | Not yet recruiting | Correlation Between Psychological Stress and Disease Progression in Newly Diagnosed Glioblastoma Patients | December 15, 2022 | December 31, 2025 | |
| NCT05756985 | Not yet recruiting | Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue | June 2024 | June 2028 | |
| NCT05653635 | Not yet recruiting | Phase 2 | Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study | September 1, 2023 | September 1, 2028 |
| NCT06448286 | Not yet recruiting | Phase 3 | PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma | June 1, 2024 | June 1, 2027 |
| NCT05900908 | Not yet recruiting | Phase 4 | Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy | May 2024 | June 2028 |
| NCT05271240 | Recruiting | Phase 3 | Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | April 27, 2022 | April 1, 2028 |
| NCT05281731 | Recruiting | N/A | Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma | April 18, 2022 | April 30, 2025 |
| NCT05296122 | Recruiting | N/A | Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesions | May 12, 2022 | July 2025 |
| NCT05556382 | Recruiting | Glioblastoma Evaluation for Heterogeneity In RadioseNsitivity | June 28, 2022 | December 2023 | |
| NCT05326464 | Recruiting | Phase 3 | Tofacitinib in Recurrent GBM Patients | October 7, 2022 | June 1, 2026 |
| NCT05342883 | Recruiting | Phase 4 | GammaTile and Stupp in Newly Diagnosed GBM | August 17, 2022 | December 1, 2027 |
| NCT05353530 | Recruiting | Phase 1 | Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (IMPACT) | July 25, 2023 | December 2042 |
| NCT05376800 | Recruiting | Phase 1 | A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma | November 30, 2022 | December 20, 2027 |
| NCT05383872 | Recruiting | N/A | Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors | August 8, 2022 | March 2025 |
| NCT05432518 | Recruiting | Early Phase 1 | Pilot Trial for Treatment of Recurrent Glioblastoma | June 27, 2023 | December 1, 2027 |
| NCT05450744 | Recruiting | Phase 1 | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) | April 1, 2023 | June 2025 |
| NCT05463848 | Recruiting | Phase 2 | Surgical Pembro +/- Olaparib w TMZ for rGBM | October 21, 2022 | December 1, 2025 |
| NCT06108206 | Recruiting | N/A | Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma | January 30, 2024 | December 31, 2026 |
| NCT03297125 | Recruiting | Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI | December 1, 2017 | December 31, 2023 | |
| NCT03643549 | Recruiting | Phase 1/Phase 2 | Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) | August 30, 2018 | December 31, 2025 |
| NCT02287428 | Recruiting | Phase 1 | Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM | November 2014 | June 2026 |
| NCT03663725 | Recruiting | Phase 3 | Treatment Intensification With Temozolomide in Adults With a Glioblastoma | March 13, 2019 | November 1, 2027 |
| NCT06090903 | Recruiting | N/A | Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma | April 14, 2022 | April 18, 2028 |
| NCT03194971 | Recruiting | NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy | June 1, 2017 | May 31, 2027 | |
| NCT03718767 | Recruiting | Phase 2 | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | March 27, 2019 | February 27, 2026 |
| NCT02902757 | Recruiting | N/A | FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma | August 25, 2015 | August 25, 2025 |
| NCT03107780 | Recruiting | Phase 1 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | July 9, 2018 | December 31, 2024 |
| NCT06058988 | Recruiting | Phase 2 | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | September 22, 2023 | September 22, 2027 |
| NCT03739333 | Recruiting | N/A | Early Diagnosis of Pseudoprogression Using 11C-Methionine PET-MRI After Concomitant Radiochemotherapy Treatment for Glioblastoma. | February 26, 2019 | January 26, 2025 |
| NCT06297512 | Recruiting | Phase 2 | Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | December 9, 2022 | March 9, 2028 |
| NCT03213002 | Recruiting | Phase 1/Phase 2 | Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM | June 13, 2017 | June 2026 |
| NCT03746080 | Recruiting | Phase 2 | Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma | December 4, 2018 | July 2027 |
| NCT03749187 | Recruiting | Phase 1 | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas | April 3, 2019 | July 30, 2029 |
| NCT02861898 | Recruiting | Phase 1/Phase 2 | Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma | June 2016 | December 2026 |
| NCT06283927 | Recruiting | The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) | January 1, 2023 | January 1, 2028 | |
| NCT06041555 | Recruiting | MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy) | January 8, 2024 | January 8, 2029 | |
| NCT03787056 | Recruiting | N/A | Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients | December 4, 2018 | January 4, 2028 |
| NCT03395587 | Recruiting | Phase 2 | Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma | March 6, 2018 | March 6, 2027 |
| NCT03861299 | Recruiting | N/A | The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients. | April 1, 2019 | September 1, 2027 |
| NCT06038760 | Recruiting | Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO) | October 12, 2023 | December 1, 2025 | |
| NCT06418113 | Recruiting | Phase 1 | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma | March 21, 2024 | March 21, 2027 |
| NCT03897491 | Recruiting | Phase 2 | PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma | September 3, 2021 | March 2027 |
| NCT03919071 | Recruiting | Phase 2 | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | February 20, 2020 | September 30, 2027 |
| NCT03922984 | Recruiting | N/A | Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma | April 16, 2019 | April 16, 2027 |
| NCT01985087 | Recruiting | Phase 1/Phase 2 | A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 | September 2014 | May 2025 |
| NCT03008148 | Recruiting | Phase 2/Phase 3 | Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM | October 11, 2018 | April 2025 |
| NCT02800486 | Recruiting | Phase 2 | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | May 2016 | May 2026 |
| NCT03970447 | Recruiting | Phase 2/Phase 3 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | July 30, 2019 | June 2028 |
| NCT06279767 | Recruiting | Phase 1/Phase 2 | Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma | July 1, 2022 | July 31, 2025 |
| NCT02977780 | Recruiting | Phase 2 | INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | February 9, 2017 | December 31, 2025 |
| NCT03975829 | Recruiting | Phase 4 | Pediatric Long-Term Follow-up and Rollover Study | November 4, 2019 | May 29, 2026 |
| NCT03975959 | Recruiting | N/A | Memory Perception Assessment in Central/Non-central Nervous System Cancers | May 10, 2019 | October 30, 2024 |
| NCT06001281 | Recruiting | N/A | Predictive Value of Soluble CD146 in Glioblastoma Patients | January 30, 2024 | December 2026 |
| NCT06273176 | Recruiting | The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma | January 1, 2023 | January 1, 2028 | |
| NCT05986851 | Recruiting | Phase 2 | Azeliragon in MGMT Unmethylated Glioblastoma | September 12, 2023 | June 30, 2025 |
| NCT04007185 | Recruiting | Surgically Induced Neurological Deficits in Glioblastomas (SIND Study) | May 15, 2021 | December 2024 | |
| NCT03452774 | Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | January 1, 2018 | June 2027 | |
| NCT05979064 | Recruiting | N/A | Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) | April 4, 2023 | April 2027 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04047264 | Recruiting | N/A | Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies | January 1, 2020 | September 1, 2027 |
| NCT05970757 | Recruiting | N/A | Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma | July 14, 2022 | July 14, 2026 |
| NCT01849952 | Recruiting | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas | February 28, 2020 | May 2024 | |
| NCT04049669 | Recruiting | Phase 2 | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | October 2, 2019 | October 2, 2027 |
| NCT05954858 | Recruiting | N/A | Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma | June 29, 2023 | June 30, 2026 |
| NCT05929456 | Recruiting | Phase 1 | Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid) | May 5, 2023 | January 1, 2025 |
| NCT05917145 | Recruiting | Phase 1 | Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors | January 17, 2024 | February 2029 |
| NCT05902169 | Recruiting | Phase 3 | Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM | January 29, 2024 | June 30, 2028 |
| NCT04135807 | Recruiting | Early Phase 1 | Implantable Microdevice In Primary Brain Tumors | March 3, 2020 | February 1, 2024 |
| NCT04181684 | Recruiting | N/A | LITT Followed by Hypofractionated RT for Recurrent Gliomas | January 8, 2020 | December 2026 |
| NCT04188535 | Recruiting | N/A | Serial MRI Scans During Radiation Therapy | January 15, 2020 | July 31, 2025 |
| NCT05879367 | Recruiting | Phase 1 | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma | July 24, 2023 | December 15, 2024 |
| NCT05871021 | Recruiting | Phase 2 | Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma | April 10, 2024 | July 10, 2027 |
| NCT04209790 | Recruiting | Phase 2 | Neoadjuvant Chemoradiation for Resectable Glioblastoma | April 1, 2020 | December 31, 2026 |
| NCT06186401 | Recruiting | Phase 1 | Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells | March 4, 2024 | May 31, 2030 |
| NCT04243005 | Recruiting | N/A | Supramarginal Resection in Glioblastoma | July 1, 2020 | March 2030 |
| NCT04266977 | Recruiting | N/A | Restrictive Use of Dexamethasone in Glioblastoma | May 8, 2020 | April 2026 |
| NCT06183983 | Recruiting | N/A | Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma | January 3, 2024 | August 2026 |
| NCT05835687 | Recruiting | Phase 1 | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | April 27, 2023 | March 2028 |
| NCT04315584 | Recruiting | Early Phase 1 | FDG and FDOPA PET Demonstration of Functional Brain Abnormalities | March 15, 2020 | June 20, 2024 |
| NCT04319276 | Recruiting | Phase 1 | Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma | November 11, 2022 | December 2026 |
| NCT04323046 | Recruiting | Phase 1 | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | October 2, 2020 | March 1, 2029 |
| NCT04359745 | Recruiting | Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression | March 21, 2019 | May 26, 2025 | |
| NCT04391062 | Recruiting | Phase 2 | Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma | September 28, 2021 | September 2025 |
| NCT04391595 | Recruiting | Early Phase 1 | LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | July 8, 2020 | February 2025 |
| NCT05798507 | Recruiting | Early Phase 1 | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | July 28, 2023 | October 31, 2025 |
| NCT05793021 | Recruiting | N/A | FKBP51s: a New Molecular Biomarker for Glioblastoma? Pre- and Post-operative Blood Levels Evaluation of FKBP51s Protein and Correlation With MRI Phenotype | July 8, 2021 | December 31, 2025 |
| NCT05781321 | Recruiting | Phase 2 | Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | March 23, 2023 | March 2, 2028 |
| NCT03152318 | Recruiting | Phase 1 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | July 18, 2017 | December 2025 |
| NCT04443010 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma | January 20, 2021 | December 2026 |
| NCT04469075 | Recruiting | Phase 2 | Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields | July 9, 2020 | July 2025 |
| NCT04474353 | Recruiting | Phase 1 | Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma | May 21, 2021 | November 2024 |
| NCT04478279 | Recruiting | Phase 1/Phase 2 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | July 1, 2020 | December 2025 |
| NCT02685605 | Recruiting | Phase 3 | Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme | December 9, 2016 | June 2026 |
| NCT04479696 | Recruiting | N/A | Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors | June 5, 2019 | February 2, 2027 |
| NCT03251027 | Recruiting | N/A | Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma | July 17, 2017 | December 31, 2025 |
| NCT05773326 | Recruiting | Early Phase 1 | Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG | May 15, 2023 | April 30, 2026 |
| NCT04523688 | Recruiting | Phase 2 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma | March 25, 2021 | December 2025 |
| NCT04528680 | Recruiting | Phase 1/Phase 2 | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma | October 29, 2020 | September 2025 |
| NCT03548571 | Recruiting | Phase 2/Phase 3 | Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy | April 26, 2018 | May 1, 2026 |
| NCT05695976 | Recruiting | GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM | April 18, 2023 | January 2029 | |
| NCT05686798 | Recruiting | Phase 1 | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | November 29, 2022 | October 2024 |
| NCT04817254 | Recruiting | Phase 2 | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | December 8, 2021 | December 31, 2026 |
| NCT04822688 | Recruiting | Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues | February 3, 2021 | December 31, 2024 | |
| NCT04825275 | Recruiting | Early Phase 1 | Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial | February 8, 2022 | January 2025 |
| NCT05669820 | Recruiting | Phase 2/Phase 3 | Antisecretory Factor Glioblastoma Phase 2 | January 15, 2024 | January 1, 2026 |
| NCT05664464 | Recruiting | Phase 1/Phase 2 | Glutamate Inhibitors in Glioblastoma | January 1, 2023 | December 2026 |
| NCT05664243 | Recruiting | Phase 1/Phase 2 | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | September 8, 2023 | December 2025 |
| NCT04863950 | Recruiting | Phase 2 | Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma | May 25, 2022 | September 2025 |
| NCT04869449 | Recruiting | Early Phase 1 | Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas | May 12, 2022 | January 2025 |
| NCT05660369 | Recruiting | Phase 1 | CARv3-TEAM-E T Cells in Glioblastoma | March 22, 2023 | June 1, 2026 |
| NCT04881032 | Recruiting | Phase 1/Phase 2 | AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma | March 7, 2022 | March 2027 |
| NCT04910022 | Recruiting | Phase 1/Phase 2 | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | December 1, 2021 | November 30, 2025 |
| NCT04922723 | Recruiting | Phase 1/Phase 2 | Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma | October 3, 2022 | August 2024 |
| NCT04937413 | Recruiting | Early Phase 1 | The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation | October 8, 2021 | June 2025 |
| NCT05635734 | Recruiting | Phase 1/Phase 2 | Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma | September 5, 2023 | December 2025 |
| NCT05629702 | Recruiting | Phase 2 | ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids | February 3, 2023 | February 2027 |
| NCT04982926 | Recruiting | Phase 1 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | September 16, 2021 | June 2025 |
| NCT05607407 | Recruiting | Phase 2 | Methimazole in Patients With Progressive Glioblastoma | January 30, 2023 | January 2026 |
| NCT05015543 | Recruiting | N/A | Physical Training in Glioblastoma Patients During Cytotoxic Therapy | July 23, 2020 | December 31, 2024 |
| NCT06129760 | Recruiting | N/A | Glioblastoma Remote Monitoring and Care - Research Protocol | April 30, 2024 | January 1, 2027 |
| NCT05600491 | Recruiting | Phase 3 | A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme | November 8, 2015 | December 1, 2025 |
| NCT05062772 | Recruiting | Brain Tumor Intraoperative Ultrasound Database | May 25, 2022 | December 30, 2023 | |
| NCT05590689 | Recruiting | Phase 1/Phase 2 | Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor | November 9, 2022 | January 2025 |
| NCT05076513 | Recruiting | Early Phase 1 | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | October 29, 2021 | February 2025 |
| NCT05095376 | Recruiting | Phase 3 | Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma | November 29, 2021 | August 8, 2031 |
| NCT05099003 | Recruiting | Phase 1/Phase 2 | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | May 31, 2022 | June 30, 2027 |
| NCT05099068 | Recruiting | N/A | Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET) | November 16, 2021 | September 15, 2025 |
| NCT05106296 | Recruiting | Phase 1 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | February 8, 2022 | September 2026 |
| NCT05109728 | Recruiting | Phase 1 | A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. | May 10, 2022 | July 28, 2026 |
| NCT05565118 | Recruiting | Phase 1 | Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression | April 9, 2024 | January 1, 2026 |
| NCT06118723 | Recruiting | The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) | January 1, 2022 | January 1, 2028 | |
| NCT05139277 | Recruiting | N/A | Evaluation of the CONVIVO System | June 28, 2022 | June 2025 |
| NCT03603405 | Recruiting | Phase 1/Phase 2 | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | February 28, 2018 | December 31, 2025 |
| NCT05168423 | Recruiting | Phase 1 | CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM | February 24, 2023 | December 19, 2039 |
| NCT06348693 | Recruiting | Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness | April 19, 2017 | November 21, 2025 | |
| NCT05182905 | Recruiting | Early Phase 1 | AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients | March 9, 2022 | January 2025 |
| NCT05183204 | Recruiting | Phase 2 | Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma | February 14, 2022 | December 2025 |
| NCT05186064 | Recruiting | N/A | Glioblastoma Targeted Treatment Option Maximization by WGS | July 25, 2022 | July 1, 2025 |
| NCT02394626 | Recruiting | Phase 2 | Surgery for Recurrent Glioblastoma | May 1, 2015 | December 2025 |
| NCT05557292 | Recruiting | Phase 1 | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | April 3, 2023 | December 31, 2025 |
| NCT05231655 | Recruiting | Ex VIvo DEtermiNed Cancer Therapy | July 7, 2021 | January 2027 | |
| NCT05236036 | Recruiting | Phase 1 | Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma | August 8, 2022 | January 3, 2027 |
| NCT05241392 | Recruiting | Phase 1 | Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma | January 27, 2022 | December 31, 2024 |
| NCT02372409 | Recruiting | Phase 2 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors | August 14, 2015 | August 31, 2030 |
| NCT04732065 | Recruiting | Phase 1 | ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors | August 23, 2021 | December 31, 2027 |
| NCT04734444 | Recruiting | N/A | SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue | September 1, 2021 | January 1, 2024 |
| NCT05700955 | Recruiting | Phase 1 | Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma | November 1, 2022 | January 2025 |
| NCT04747145 | Recruiting | Phase 2 | Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma | June 3, 2021 | June 2026 |
| NCT04752280 | Recruiting | N/A | Glioblastoma Radiotherapy Using IMRT or Proton Beams | April 19, 2021 | October 19, 2027 |
| NCT04752813 | Recruiting | Phase 2 | A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) | August 22, 2022 | December 30, 2025 |
| NCT05698524 | Recruiting | Phase 1 | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma | June 26, 2023 | June 2027 |
| NCT04541082 | Recruiting | Phase 1 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | October 26, 2020 | February 2025 |
| NCT05772767 | Recruiting | N/A | Modulation of Ciliogenesis in Glioma Stem Cells | February 15, 2021 | February 28, 2024 |
| NCT05772741 | Recruiting | N/A | Grafts of GSCs Into Brain Organoids for Testing Anti-invasion Drugs | December 3, 2018 | December 31, 2023 |
| NCT05768919 | Recruiting | Phase 1/Phase 2 | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | March 3, 2023 | May 2027 |
| NCT05768087 | Recruiting | N/A | Escalated Dose Proton Therapy Within the Multimodality Treatment of Glioblastoma Patients | April 15, 2024 | May 2029 |
| NCT04555577 | Recruiting | Phase 1 | Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma | September 20, 2020 | October 30, 2025 |
| NCT04559230 | Recruiting | Phase 2 | Sacituzumab Govitecan in Recurrent Glioblastoma | January 6, 2022 | February 2025 |
| NCT05759195 | Recruiting | N/A | Biomolecular Analysis for Predicting Response to Regorafenib | January 7, 2021 | December 31, 2024 |
| NCT04573192 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression | February 19, 2021 | December 2025 |
| NCT04574856 | Recruiting | Phase 2 | Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | November 4, 2020 | July 2024 |
| NCT04590664 | Recruiting | Phase 1/Phase 2 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | January 15, 2021 | August 15, 2025 |
| NCT06147505 | Recruiting | Phase 1/Phase 2 | Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM) | October 29, 2023 | December 29, 2025 |
| NCT05753995 | Recruiting | N/A | Immuno-Positron Emission Tomography (PET)-Glioma Study, a Proof-of-principle Imaging Study | March 1, 2024 | December 1, 2026 |
| NCT02611024 | Recruiting | Phase 1/Phase 2 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | May 6, 2016 | March 2026 |
| NCT03529448 | Recruiting | Phase 1/Phase 2 | TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma | August 18, 2023 | December 2025 |
| NCT04614909 | Recruiting | Early Phase 1 | Study of Pamiparib in Newly Diagnosed and rGBM | January 11, 2021 | December 2024 |
| NCT04623931 | Recruiting | Phase 2 | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | January 30, 2020 | December 31, 2026 |
| NCT05753007 | Recruiting | Phase 2 | A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients | February 15, 2024 | September 2025 |
| NCT05735171 | Recruiting | N/A | Supramarginal Resection in Glioblastoma Guided by Artificial Intelligence | February 1, 2023 | June 30, 2026 |
| NCT06146738 | Recruiting | The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) | January 1, 2023 | January 1, 2029 | |
| NCT04656535 | Recruiting | Early Phase 1 | AB154 Combined With AB122 for Recurrent Glioblastoma | April 21, 2021 | December 31, 2025 |
| NCT04657146 | Recruiting | Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma | February 5, 2024 | November 1, 2025 | |
| NCT06146725 | Recruiting | The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) | January 1, 2023 | January 1, 2029 | |
| NCT04661384 | Recruiting | Phase 1 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | March 5, 2021 | November 17, 2025 |
| NCT04678648 | Recruiting | Phase 1 | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | February 16, 2021 | March 5, 2024 |
| NCT06140875 | Recruiting | N/A | Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF) | November 15, 2023 | May 14, 2029 |
| NCT04691960 | Recruiting | Phase 2 | A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging | August 2016 | December 2024 |
| NCT04699773 | Recruiting | N/A | LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138) | February 20, 2021 | December 2027 |
| NCT04708171 | Recruiting | The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections | January 1, 2022 | October 1, 2026 | |
| NCT04717739 | Recruiting | TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study | December 30, 2021 | February 1, 2025 | |
| NCT04730869 | Recruiting | N/A | Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma | May 26, 2021 | December 1, 2024 |
| NCT04222309 | Suspended | Phase 1 | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) | January 6, 2020 | January 31, 2025 |
| NCT03197506 | Suspended | Phase 2 | Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | September 15, 2017 | August 31, 2024 |
| NCT04219475 | Suspended | Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients | January 2023 | December 2025 | |
| NCT03055208 | Suspended | N/A | Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma | February 8, 2017 | May 9, 2023 |
| NCT03287063 | Suspended | Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma | July 5, 2018 | October 2024 | |
| NCT03868943 | Suspended | Phase 2 | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma | January 27, 2021 | July 2025 |
| NCT03717142 | Suspended | N/A | Feasibility of the LUM Imaging System for Detection of Cancer to the Brain | May 3, 2019 | September 2025 |
| NCT04963413 | Terminated | Phase 1 | RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. | January 13, 2022 | September 28, 2023 |
| NCT03119064 | Terminated | Phase 1/Phase 2 | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma | November 30, 2017 | October 8, 2021 |
| NCT03149575 | Terminated | Phase 3 | VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM | October 27, 2017 | August 31, 2019 |
| NCT03151772 | Terminated | Early Phase 1 | Bioavailability of Disulfiram and Metformin in Glioblastomas | January 29, 2018 | September 24, 2020 |
| NCT03115138 | Terminated | N/A | Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas. | March 9, 2016 | November 6, 2017 |
| NCT03246113 | Terminated | Phase 1 | Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma | March 19, 2018 | May 9, 2019 |
| NCT03250299 | Terminated | Phase 1 | Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | June 7, 2017 | August 24, 2022 |
| NCT03293888 | Terminated | Spectral Analysis Probe to Identify Glioblastoma Cells | October 31, 2017 | September 30, 2018 | |
| NCT02905643 | Terminated | Discerning Pseudoprogression vs True Tumor Growth in GBMs | September 2016 | February 13, 2018 | |
| NCT03363659 | Terminated | Phase 2 | Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme | March 28, 2018 | January 13, 2022 |
| NCT02880410 | Terminated | Phase 1 | Feasibility Study on LITT for Newly Diagnosed Glioblastoma | August 15, 2017 | September 14, 2018 |
| NCT02864368 | Terminated | Phase 1 | Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens | December 7, 2016 | June 15, 2020 |
| NCT03393000 | Terminated | Phase 3 | Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects | January 16, 2018 | November 6, 2020 |
| NCT03403803 | Terminated | Prognosis and Therapeutic Biomarkers for Glioblastoma Patients | September 1, 2017 | March 25, 2019 | |
| NCT02841332 | Terminated | N/A | Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma | May 2013 | December 2016 |
| NCT03422094 | Terminated | Phase 1 | Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | October 31, 2018 | December 31, 2020 |
| NCT02833701 | Terminated | Phase 1 | Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma | March 2016 | March 2019 |
| NCT02769806 | Terminated | Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma | May 23, 2016 | June 21, 2019 | |
| NCT02743078 | Terminated | Phase 2 | Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | May 9, 2017 | October 15, 2019 |
| NCT02709889 | Terminated | Phase 1/Phase 2 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | September 23, 2016 | August 27, 2019 |
| NCT02664363 | Terminated | Phase 1 | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma | February 1, 2017 | September 12, 2019 |
| NCT02663271 | Terminated | Phase 2 | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma | December 19, 2016 | June 11, 2021 |
| NCT02648633 | Terminated | Phase 1 | Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma | May 24, 2016 | February 21, 2017 |
| NCT02465528 | Terminated | Phase 2 | Ceritinib Rare Indications Study in ALK+ Tumors | May 6, 2016 | August 20, 2018 |
| NCT03593993 | Terminated | A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas | May 19, 2018 | July 7, 2023 | |
| NCT02394665 | Terminated | Phase 2 | Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma | March 2015 | September 2016 |
| NCT02329795 | Terminated | Image-derived Prediction of Response to Chemo-radiation in Glioblastoma | October 2014 | October 2016 | |
| NCT02254954 | Terminated | Phase 1 | Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma | January 8, 2015 | September 29, 2016 |
| NCT02227576 | Terminated | Phase 2 | Prevention of Thrombocytopenia in Glioblastoma Patients | July 10, 2014 | December 14, 2017 |
| NCT03705351 | Terminated | Phase 1 | Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM | December 2, 2019 | February 24, 2022 |
| NCT03707457 | Terminated | Phase 1 | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | March 22, 2019 | June 18, 2020 |
| NCT03714334 | Terminated | Phase 1 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | October 16, 2018 | April 5, 2023 |
| NCT02176720 | Terminated | Phase 1 | Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma | May 2014 | March 2016 |
| NCT02168270 | Terminated | Phase 1 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | June 16, 2014 | August 20, 2015 |
| NCT02133183 | Terminated | Phase 1 | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | July 2, 2014 | October 31, 2023 |
| NCT02129335 | Terminated | Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner | April 2014 | May 2017 | |
| NCT02085304 | Terminated | Phase 1/Phase 2 | Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM | May 7, 2013 | May 29, 2018 |
| NCT02062372 | Terminated | N/A | Spatial Analysis and Validation of Glioblastoma on 7 T MRI | December 10, 2014 | February 5, 2018 |
| NCT02039778 | Terminated | N/A | Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma | December 2013 | December 2015 |
| NCT02025231 | Terminated | Phase 1/Phase 2 | Image Guided Reirradiation of High-grade Glioma | December 2011 | April 2015 |
| NCT03861598 | Terminated | Early Phase 1 | Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells | July 19, 2019 | June 17, 2021 |
| NCT01986348 | Terminated | Phase 2 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas | March 3, 2014 | January 23, 2020 |
| NCT03927222 | Terminated | Phase 2 | Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma | September 30, 2019 | February 10, 2023 |
| NCT03939858 | Terminated | Bioenergetic Profiling and Cognition in GBM Patients | October 24, 2019 | June 9, 2023 | |
| NCT01954576 | Terminated | N/A | NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | October 10, 2013 | May 14, 2021 |
| NCT03971734 | Terminated | Phase 1 | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas | December 6, 2019 | October 2, 2023 |
| NCT03973918 | Terminated | Phase 2 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG | July 29, 2019 | October 1, 2023 |
| NCT04002804 | Terminated | Phase 1 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Recurrence Of Glioblastoma Multiforme | April 2010 | June 13, 2017 |
| NCT01898273 | Terminated | Phase 2 | Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma | February 2014 | December 2015 |
| NCT01836549 | Terminated | Phase 2 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | March 2013 | April 2016 |
| NCT04221061 | Terminated | Early Phase 1 | 18F-FluorThanatrace (PET/CT) in Glioblastoma | February 20, 2020 | June 10, 2024 |
| NCT01721577 | Terminated | Phase 1/Phase 2 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas | December 2012 | December 2015 |
| NCT01702792 | Terminated | Phase 1 | Derivation of Tumor Specific Hybridomas | January 2014 | May 6, 2015 |
| NCT01700569 | Terminated | Phase 1 | Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma | January 2013 | April 16, 2021 |
| NCT04424966 | Terminated | Early Phase 1 | Infigratinib in Recurrent High-Grade Glioma Patients | July 21, 2020 | April 27, 2023 |
| NCT01507506 | Terminated | Phase 3 | Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma | March 15, 2011 | January 2, 2020 |
| NCT01499251 | Terminated | Phase 1 | Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma | January 2012 | April 2016 |
| NCT04541225 | Terminated | Phase 1 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | December 8, 2020 | August 31, 2022 |
| NCT01403285 | Terminated | Phase 1 | Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma | August 2011 | April 2014 |
| NCT01392352 | Terminated | Phase 2 | HYPAZ: Hypertension Induced by Pazopanib | April 2011 | September 2015 |
| NCT01351519 | Terminated | Phase 2 | A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors | May 2011 | January 2015 |
| NCT04608812 | Terminated | Phase 1 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection | March 2, 2021 | February 27, 2023 |
| NCT01310855 | Terminated | Phase 2 | Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma | May 2011 | January 2014 |
| NCT01260467 | Terminated | Phase 2 | Memantine for Recurrent Glioblastoma | November 2010 | April 2014 |
| NCT01227434 | Terminated | Phase 2 | A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma | September 2010 | December 2013 |
| NCT04681677 | Terminated | Phase 2 | Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab | November 2, 2021 | April 24, 2024 |
| NCT04763031 | Terminated | N/A | Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT | March 5, 2021 | November 3, 2023 |
| NCT01105988 | Terminated | Early Phase 1 | Evaluating Tumor Pseudoprogression With FLT-PET and MRI | May 2011 | October 2011 |
| NCT01095094 | Terminated | Phase 2 | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | January 2009 | November 2011 |
| NCT01086345 | Terminated | Early Phase 1 | Radiosurgery Plus Bevacizumab in Glioblastoma | February 2010 | December 2014 |
| NCT01044225 | Terminated | Phase 2 | Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma | September 2009 | September 2011 |
| NCT05074992 | Terminated | Phase 2 | A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma | August 24, 2022 | May 2, 2023 |
| NCT01011231 | Terminated | Phase 2 | Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma | December 2009 | April 2011 |
| NCT00948389 | Terminated | Phase 1/Phase 2 | Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) | October 2009 | May 2011 |
| NCT00895960 | Terminated | Phase 1 | Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma | May 7, 2009 | August 2013 |
| NCT00790452 | Terminated | Phase 2 | Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma | November 2008 | October 2009 |
| NCT00761280 | Terminated | Phase 3 | Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | December 2008 | June 2012 |
| NCT00734526 | Terminated | Phase 1 | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | December 18, 2008 | December 2012 |
| NCT00669669 | Terminated | Phase 1/Phase 2 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | February 25, 2009 | January 20, 2021 |
| NCT00365222 | Terminated | Phase 2 | Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | July 2006 | June 2007 |
| NCT00171938 | Terminated | Phase 2 | Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) | April 2004 | June 2006 |
| NCT00115453 | Terminated | Phase 1/Phase 2 | Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma | May 1999 | August 2008 |
| NCT02520635 | Unknown status | Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients | January 2015 | December 2020 | |
| NCT04313842 | Unknown status | A Explorative Study to Evaluate the Clinical Feasibility of AVATAMED | July 1, 2019 | January 1, 2022 | |
| NCT01759810 | Unknown status | Phase 2/Phase 3 | Proteome-based Personalized Immunotherapy of Glioblastoma | December 2012 | December 2020 |
| NCT01765088 | Unknown status | Phase 3 | A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas | September 2012 | December 2019 |
| NCT00521482 | Unknown status | Phase 2 | Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma | September 2007 | January 2009 |
| NCT01798771 | Unknown status | N/A | Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery | March 2013 | February 2016 |
| NCT01811121 | Unknown status | Phase 3 | MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS | February 2013 | August 2019 |
| NCT00392548 | Unknown status | URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol | October 2006 | October 2006 | |
| NCT03025893 | Unknown status | Phase 2/Phase 3 | A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme | August 31, 2018 | January 1, 2022 |
| NCT01903330 | Unknown status | Phase 2 | ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | March 2014 | March 2023 |
| NCT01939574 | Unknown status | N/A | A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma | August 2013 | September 2016 |
| NCT03869242 | Unknown status | N/A | NovoTTF-200A Together With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GBM | October 1, 2018 | December 1, 2021 |
| NCT02047058 | Unknown status | Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics | March 2014 | March 2017 | |
| NCT03734913 | Unknown status | Phase 1 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | January 25, 2019 | July 31, 2021 |
| NCT03687034 | Unknown status | Phase 1 | A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma | June 1, 2019 | December 31, 2020 |
| NCT03152708 | Unknown status | CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma | November 1, 2017 | December 31, 2017 | |
| NCT03631836 | Unknown status | Phase 1 | Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma | January 1, 2019 | January 1, 2022 |
| NCT02345824 | Unknown status | Phase 1 | Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma | March 2016 | January 2020 |
| NCT02430363 | Unknown status | Phase 1/Phase 2 | Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 | March 2013 | June 2018 |
| NCT03567135 | Unknown status | Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma | October 1, 2017 | October 1, 2020 | |
| NCT02585219 | Unknown status | Pilot Viability of 11C-MET-PET as a Post-surgery Baseline Scan in High-grade Gliomas | January 2016 | July 2017 | |
| NCT02629757 | Unknown status | Phase 3 | A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas | April 2015 | May 2023 |
| NCT02715297 | Unknown status | Phase 2 | Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma | February 2016 | February 2023 |
| NCT03463733 | Unknown status | Phase 1 | Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma) | March 2, 2018 | June 1, 2022 |
| NCT02766699 | Unknown status | Phase 1 | A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) | October 25, 2016 | June 2020 |
| NCT02772094 | Unknown status | Phase 2 | Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas) | May 2005 | December 2016 |
| NCT03392545 | Unknown status | Phase 1 | Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1) | April 1, 2018 | June 1, 2020 |
| NCT02904525 | Unknown status | N/A | Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine Model | June 2015 | April 30, 2021 |
| NCT02910804 | Unknown status | Early Phase 1 | IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma | November 2015 | December 2018 |
| NCT03294486 | Unknown status | Phase 1/Phase 2 | Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients | October 12, 2017 | September 2021 |
| NCT03278249 | Unknown status | N/A | Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma | October 12, 2017 | January 1, 2022 |
| NCT03258021 | Unknown status | TTFields In GErmany in Routine Clinical Care | August 31, 2017 | July 2021 | |
| NCT03233152 | Unknown status | Phase 1 | Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma | November 17, 2016 | November 17, 2023 |
| NCT00045968 | Unknown status | Phase 3 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer | December 2006 | |
| NCT05375318 | Unknown status | BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels | March 1, 2021 | July 1, 2022 | |
| NCT03231501 | Unknown status | Phase 1 | HMPL-813 in Treating Patients With Glioblastoma | January 26, 2018 | August 31, 2020 |
| NCT05131763 | Unknown status | Phase 1 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | March 1, 2021 | December 1, 2023 |
| NCT05063682 | Unknown status | Phase 1 | The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients | May 15, 2020 | October 2023 |
| NCT04998864 | Unknown status | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients | August 25, 2021 | December 30, 2023 | |
| NCT01083719 | Unknown status | Phase 2 | A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes. | April 2010 | August 2011 |
| NCT04970615 | Unknown status | Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models | May 15, 2021 | December 15, 2023 | |
| NCT03144167 | Unknown status | N/A | Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy | August 20, 2017 | January 20, 2021 |
| NCT04959500 | Unknown status | Phase 2 | Newly Diagnosed Glioblastoma | June 10, 2021 | October 31, 2023 |
| NCT04902586 | Unknown status | N/A | Effect of Radiotherapy Concurrent of TTFields in Patients With Glioblastoma | June 19, 2021 | July 19, 2022 |
| NCT04874506 | Unknown status | Phase 2 | MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) | June 1, 2021 | August 2023 |
| NCT04856852 | Unknown status | N/A | Iodine-125 Brachytherapy Together With Chemotherapy in Patients With Newly Diagnosed Glioblastoma | June 28, 2021 | August 31, 2023 |
| NCT04829097 | Unknown status | Phase 3 | Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma | November 1, 2020 | November 1, 2023 |
| NCT01208909 | Unknown status | Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI) | August 2009 | December 2011 | |
| NCT04801147 | Unknown status | Phase 1/Phase 2 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme | June 2010 | December 2023 |
| NCT00643825 | Unknown status | Phase 2 | Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients | January 2008 | January 2012 |
| NCT04772846 | Unknown status | Phase 1/Phase 2 | Chloroquine for Glioblastoma. | March 1, 2018 | March 2021 |
| NCT01308632 | Unknown status | Phase 2/Phase 3 | Metronomic Temozolamide in Patients With Recurrent Glioblastoma | November 2007 | June 2012 |
| NCT04583020 | Unknown status | Phase 2 | Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma | November 12, 2020 | December 31, 2023 |
| NCT04566185 | Unknown status | Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma | December 16, 2020 | September 2022 | |
| NCT04552977 | Unknown status | Phase 2 | A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma | September 2020 | August 2022 |
| NCT04547855 | Unknown status | Phase 2 | Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen | September 11, 2020 | March 11, 2023 |
| NCT01579253 | Unknown status | Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients | April 2012 | ||
| NCT04417933 | Unknown status | Early Phase 1 | Tumor Electric Fields Treatment System for Glioblastoma | April 7, 2020 | May 2021 |
| NCT01637753 | Unknown status | N/A | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma | June 2012 | December 2013 |
| NCT04388033 | Unknown status | Phase 1/Phase 2 | Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. | December 2020 | December 2023 |
| NCT01656980 | Unknown status | Phase 3 | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | August 2012 | December 2014 |
| NCT05218408 | Withdrawn | Phase 1/Phase 2 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type | March 8, 2022 | May 2024 |
| NCT05304663 | Withdrawn | Phase 1 | Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression | June 1, 2022 | December 31, 2024 |
| NCT05410301 | Withdrawn | N/A | Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma | April 2023 | August 2026 |
| NCT05054400 | Withdrawn | Early Phase 1 | Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR | February 5, 2020 | August 29, 2023 |
| NCT02590497 | Withdrawn | N/A | Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery | March 20, 2016 | October 26, 2017 |
| NCT04270461 | Withdrawn | Phase 1 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | March 17, 2020 | October 17, 2020 |
| NCT02599090 | Withdrawn | Phase 2 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | December 2008 | December 2012 |
| NCT02283944 | Withdrawn | Phase 2 | TMS Electrochemotherapy for Glioblastoma Multiforme | January 2015 | May 31, 2019 |
| NCT03649464 | Withdrawn | Phase 1/Phase 2 | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | August 2022 | August 2025 |
| NCT04200066 | Withdrawn | Phase 1 | A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma | June 1, 2022 | February 1, 2024 |
| NCT01782976 | Withdrawn | Phase 2 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | June 2013 | |
| NCT03506139 | Withdrawn | Phase 2 | Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma | May 15, 2019 | December 31, 2026 |
| NCT01174537 | Withdrawn | Phase 1/Phase 2 | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | July 2011 | July 2011 |
| NCT04118036 | Withdrawn | Phase 2 | Abemaciclib + Pembrolizumab In Glioblastoma | December 1, 2021 | December 1, 2024 |
| NCT01189513 | Withdrawn | Phase 1 | SCH-900105 in Recurrent Glioblastoma | August 2010 | January 2011 |
| NCT05927610 | Withdrawn | N/A | Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma | June 19, 2023 | February 15, 2024 |
| NCT00703859 | Withdrawn | Phase 1 | Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma | July 2008 | |
| NCT02919332 | Withdrawn | Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma | June 8, 2016 | December 12, 2018 | |
| NCT04105374 | Withdrawn | Phase 2/Phase 3 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | January 31, 2020 | November 30, 2030 |
| NCT04741984 | Withdrawn | Phase 1 | Monocyte Antigen Carrier Cells for Newly Diagnosed GBM | August 2023 | November 2025 |
| NCT01225510 | Withdrawn | Phase 2 | A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma | January 2011 | January 2013 |
| NCT01854099 | Withdrawn | Phase 1 | Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens | January 2014 | January 2014 |
| NCT04629209 | Withdrawn | Phase 2 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | June 28, 2024 | June 30, 2025 |
| NCT01331616 | Withdrawn | Early Phase 1 | Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab | March 2011 | July 2012 |
| NCT02876003 | Withdrawn | Phase 2 | Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma | September 2016 | October 2020 |
| NCT01861990 | Withdrawn | Phase 1 | Valproic Acid in Childhood Progressive Brain Tumors | May 2013 | December 2013 |
| NCT02432417 | Withdrawn | Phase 2 | The Addition of Chloroquine to Chemoradiation for Glioblastoma, | November 10, 2023 | November 10, 2023 |
| NCT01413438 | Withdrawn | Phase 2 | Bevacizumab With or Without Surgery for Adult Glioblastomas | July 15, 2011 | September 26, 2013 |
| NCT02754362 | Withdrawn | Phase 2 | A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma | November 2016 | June 2019 |
| NCT01441388 | Withdrawn | Phase 1 | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | December 2011 | November 2013 |
| NCT01445691 | Withdrawn | Phase 2 | More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery | November 2015 | September 2016 |
| NCT03980249 | Withdrawn | Early Phase 1 | Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells | September 2020 | June 2022 |
| NCT03956706 | Withdrawn | N/A | Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas | December 24, 2018 | September 1, 2022 |
| NCT01622764 | Withdrawn | Phase 2 | 89Zr-RO5323441 PET Imaging in Glioblastoma | September 2014 | September 2016 |
| NCT03176160 | Withdrawn | LITT Palliative Treatment for Patients With Malignant Gliomas | June 2019 | June 2022 |
- Disase is a (Disease Ontology)
- DOID:3069
- Cross Reference ID (Disease Ontology)
- GARD:2491
- Cross Reference ID (Disease Ontology)
- ICDO:9440/3
- Cross Reference ID (Disease Ontology)
- MESH:D005909
- Cross Reference ID (Disease Ontology)
- NCI:C129295
- Cross Reference ID (Disease Ontology)
- NCI:C39750
- Cross Reference ID (Disease Ontology)
- NCI:C9094
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:63634009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0017636
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0278878
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1514422
- Exact Synonym (Disease Ontology)
- adult glioblastoma multiforme
- Exact Synonym (Disease Ontology)
- GBM
- Exact Synonym (Disease Ontology)
- glioblastoma multiforme
- Exact Synonym (Disease Ontology)
- grade IV adult Astrocytic tumor
- Exact Synonym (Disease Ontology)
- primary glioblastoma multiforme
- Exact Synonym (Disease Ontology)
- spongioblastoma multiforme
- OrphaNumber from OrphaNet (Orphanet)
- 360
- MeSH unique ID (MeSH (Medical Subject Headings))
- D005909